Courtney Flaherty

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

The FDA has granted breakthrough therapy designation to zongertinib in the first line for nonsquamous NSCLC harboring HER2 TKD activating mutations.

Christopher Phillips, PharmD, discusses the advantages of liquid drug formulations over tablets and capsules for select pediatric or adult patients with cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

Andrea Necchi, MD, discusses how initial findings from the SURE-02 study indicate the potential for bladder preservation over cystectomy in MIBC.

In an OncLive® Peer Exchange, 4 panelists discuss navigating fixed-duration vs continuous therapy in CLL.

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

Following cuts to federal funding for health agencies, concerns about the long-term consequences for research programs in the US are escalating.

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

Thomas Powles, MD, MBBS, MRCP, discusses challenges in identifying a predictive biomarker of response for sasanlimab in high-risk, BCG-naive NMIBC.

Ribociclib plus trastuzumab and an AI produced a median PFS of 30.4 months in patients with hormone receptor–positive, HER2-positive breast cancer.

Four expert hematologists discuss the FDA’s decision to remove REMS programs for CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies.

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

Andrew Kuykendall, MD, discusses the evolving role of BTK inhibitors, as well as emerging targets and treatment modalities targeting BTK and BCL2 in CLL.

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic for zongertinib in NSCLC harboring HER2 TKD mutations.

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

Alberto Farolfi, MD, PhD, shares results from a real-world study of first-line bevacizumab, pembrolizumab, and platinum chemotherapy in cervical cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.

A supplemental new drug application for all-oral, fixed-duration acalabrutinib plus venetoclax in treatment-naive CLL has been submitted to the FDA.

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.